相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A study of over 114,000 participants found that slower CYP2C19 metabolizers taking escitalopram or citalopram experienced side effects significantly more often than faster metabolizers. - Slower metabolizers on escitalopram were more likely to report sleep and sexual problems, while those on sertraline had higher rates of tremor, after multiple-testing correction. - Slower CYP2C19 metabolizers were significantly more likely to discontinue escitalopram or citalopram due to side effects, with discontinuation rates of roughly 25–30% among poor metabolizers versus about 20% among ultrarapid metabolizers. - The findings underscore the potential of pharmacogenetic testing to guide personalized SSRI prescribing and reduce the trial-and-error burden in depression treatment.
- 23andMe researchers analyzed genetic data from 27,885 individuals using GLP-1 medications and identified specific variants in GLP1R and GIPR genes that predict weight loss efficacy and side effect risk. - A missense variant in the GLP1R gene was significantly associated with increased weight loss efficacy, while variations in both GLP1R and GIPR genes were linked to nausea and vomiting side effects. - The GIPR genetic variation's association with nausea and vomiting was specific to tirzepatide users but not semaglutide users, suggesting drug-specific genetic effects. - The findings enable prediction models showing weight loss estimates varying between 6% and 20% of starting weight, with nausea risk ranging from 5% to 78% based on genetics and other factors.
- ResearchAndMarkets.com has released a comprehensive report analyzing licensing deals in biotechnology from 2020 to 2025, providing insights into deal trends and structures. - The report covers hundreds of companies including major players like AbbVie, ACADIA Pharmaceuticals, and emerging biotech firms across various therapeutic areas and technology types. - Key features include financial terms analysis covering upfront payments, milestones, and royalties, plus access to actual contract documents for due diligence purposes. - The analysis enables benchmarking of transaction values and identification of the most active dealmakers in the biotechnology licensing landscape.
- The FDA has updated the capecitabine (Xeloda) drug label to require genetic testing for DPYD variants before treatment, marking a significant shift from previous optional testing recommendations. - Between 3-8% of patients carry DPYD gene variants that impair their ability to metabolize capecitabine and 5-fluorouracil, potentially leading to severe toxicity or death. - The new black box warning explicitly states that serious adverse reactions or death may occur in patients with complete DPD deficiency, requiring providers to test for genetic variants prior to initiating treatment. - Healthcare providers and diagnostic companies are now implementing clinical workflow solutions to comply with the new FDA requirements and integrate DPYD testing into standard cancer care protocols.
- Regeneron Pharmaceuticals has won the bankruptcy auction for 23andMe's assets with a $256 million bid, aiming to maintain the consumer genetics service while enhancing its drug discovery platform. - The acquisition includes 23andMe's Personal Genome Service, Total Health, Research Services, and Biobank assets, but excludes the Lemonaid Health business. - Regeneron has committed to prioritizing privacy and ethical use of customer data, working with a court-appointed Customer Privacy Ombudsman to ensure compliance with existing policies.
• Regeneron Pharmaceuticals has reached an agreement to acquire 23andMe for approximately $310 million, gaining access to one of the world's largest consumer genetic databases. • The acquisition comes as 23andMe has struggled financially in recent years, with its stock price declining significantly since going public in 2021 through a SPAC merger. • This deal represents a strategic move for Regeneron to enhance its drug discovery capabilities by leveraging 23andMe's genetic data from millions of consenting users.
- Neuralink has received approval to begin a clinical trial in Canada for its brain-computer interface, marking its first trial outside the US and focusing on patients with paralysis. - The trial will use the N1 brain implant and R1 robot to assist individuals with tetraplegia or ALS, assessing the device's ability to restore motor function. - 23andMe, after restructuring, has partnered with Mirador Therapeutics to leverage genetic data for precision medicine research in immunology and inflammation. - The collaboration aims to advance Mirador's drug development efforts by integrating 23andMe's genetic database with Mirador's Mirador 360 development engine.
- 23andMe is discontinuing its therapeutics division and laying off 40% of its workforce, impacting over 200 employees, to reduce operating expenses. - The company cites a focus on its core consumer business and research partnerships as the primary driver for this restructuring. - This decision follows a period of financial losses, a significant data breach, and the resignation of independent board members. - 23andMe anticipates saving over $35 million annually through these measures, despite incurring up to $12 million in termination-related costs.
- 23andMe's 23ME-01473 showed anti-tumor activity in preclinical models of non-small cell lung cancer, supporting its ongoing Phase 1 trial. - 23ME-00610 demonstrated a confirmed partial response in a patient with refractory clear-cell renal-cell carcinoma in Phase 2 trials. - Higher tumor expression of CD200 correlated with increased clinical benefit from 23ME-00610, suggesting its potential as a patient selection biomarker. - Data suggests 23ME-00610 may benefit patients with 'cold' tumors unresponsive to PD-1/PD-L1 checkpoint inhibitors.
- The FDA approved 23andMe's Personal Genome Service Pharmacogenetic Reports, marking the first direct-to-consumer genetic test to help patients understand how their genetics may affect responses to over 50 common prescription and over-the-counter drugs. - The test analyzes 33 genetic variants associated with drug metabolism, including responses to blood thinners like clopidogrel and mental health treatments, but comes with strict limitations prohibiting its use for treatment decisions or medical advice. - Medical experts express caution about the clinical utility of pharmacogenetic testing for general consumers, noting that while genetic variants affect drug metabolism, the clinical interpretation and prescription implications remain unclear for most patients.
